Indian Journal of Dermatology
  Publication of IADVL, WB
  Official organ of AADV
Indexed with Science Citation Index (E) , Web of Science and PubMed
 
Users online: 99  
Home About  Editorial Board  Current Issue Archives Online Early Coming Soon Guidelines Subscriptions  e-Alerts    Login  
    Small font sizeDefault font sizeIncrease font size Print this page Email this page
SPECIAL ARTICLE
Year : 2011  |  Volume : 56  |  Issue : 5  |  Page : 485-489

Consensus statement on the management of urticaria


1 Shree Skin Centre & Pathology Laboratory, Nerul, Navi Mumbai, India
2 Skin Disease Center, Nasik, India
3 Manipal Hospital, Bangalore, India
4 101, Rishabh Tower, Karkardooma, Community Center, Delhi, India
5 11, Vasant Vihar, New Delhi, India
6 Institute of Child Health, Kolkata, India
7 Urticaria Clinic, Institute of Allergic and Immunological Skin Diseases, Kolkata, India
8 Apollo Hospital, Chennai, India
9 Department of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, Germany

Correspondence Address:
Kiran V Godse
Shree Skin Centre & Pathology Laboratory, 21/22, L Market, Sector 8, Nerul (West), Navi Mumbai - 400 706
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0019-5154.87119

Rights and Permissions

This consensus statement was developed by Special Interest Group - Urticaria (IADVL). Urticaria, a heterogeneous group of diseases, often cannot be recognized by its morphology. Due to non-specific and non-affordable diagnosis, management of urticaria, especially chronic urticaria, is very challenging. This guideline includes definition, causes, classification and management of urticaria. Urticaria has a profound impact on the quality of life and causes immense distress to patients, necessitating effective treatment. One approach to manage urticaria is identification and elimination of the underlying cause(s) and/or eliciting trigger(s), while the second one is treatment aimed at providing symptomatic relief. This guideline recommends use of second-generation non-sedating H1 antihistamines as the first-line treatment. The dose can be increased up to four times to meet the expected results. In case patients still do not respond, appropriate treatment options can be selected depending on the cost.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed5810    
    Printed144    
    Emailed4    
    PDF Downloaded378    
    Comments [Add]    
    Cited by others 4    

Recommend this journal